JPMorgan Chase & Co. Grows Holdings in Progyny, Inc. (NASDAQ:PGNY)

JPMorgan Chase & Co. raised its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 15.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 425,682 shares of the company's stock after purchasing an additional 57,606 shares during the period. JPMorgan Chase & Co. owned 0.50% of Progyny worth $7,343,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PGNY. Signaturefd LLC grew its stake in shares of Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after acquiring an additional 1,355 shares during the period. GAMMA Investing LLC boosted its holdings in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after buying an additional 1,246 shares during the period. Nisa Investment Advisors LLC increased its stake in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares in the last quarter. Caitlin John LLC raised its holdings in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Progyny in the fourth quarter valued at about $74,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PGNY. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research report on Monday, March 31st. Canaccord Genuity Group lifted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, February 28th. JPMorgan Chase & Co. upped their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Finally, Bank of America lifted their price target on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Progyny presently has a consensus rating of "Hold" and a consensus price target of $23.64.

Progyny Stock Performance

PGNY stock traded up $0.50 during midday trading on Tuesday, reaching $21.87. 1,426,368 shares of the company traded hands, compared to its average volume of 1,743,543. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.71, a P/E/G ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a 52-week low of $13.39 and a 52-week high of $33.84. The business has a 50 day moving average of $21.93 and a 200-day moving average of $18.94.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.